The University of Verona has launched a call for applications for one PhD position within the ITN project “DIRNANO – Directing the immune response through designed nanomaterials”, funded from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956544.
DIRNANO is an interdisciplinary training programme for next-generation early-stage researchers at the interface of nanopharmaceutical bioengineering and its translation on preclinical and human immunology.
DIRNANO will develop biocompatible nanopharmaceuticals with either “super”-stealth or immune-specific behaviour for cancer immunotherapy and vaccination by mapping nanoparticle-immune interactions.
The project is coordinated by the University of Padova, and includes internationally renowned scientists and industrialists at the forefront of nano-engineering, pharmaceutical sciences, molecular biosciences, commerce and business.
The position at the University of Verona
The University of Verona will hire one early-stage researcher to carry out the research project ESR09 – “Development of therapeutic cancer nanovaccine candidates” under the supervision of Prof Roberto Fiammengo. The researhcer will be integrated within the group of Organic Chemistry and Nanobiointeractions of the Department of Biotechnology.
The selected candidate will be employed and enrolled in the PhD in Biotechnology. The PhD programme lasts for three years, starting from 1st of February 2021, and will end with the defence of the doctoral thesis, which must take place by 2024.
Applicants can submit their application from 1st of October 2020 to 15th November 2020 at noon.
Further information is available at this webpage: https://www.dbt.univr.it/?ent=iscrizionecs&cs=624&lang=en#iscrizioni-cs-concorso1